Planning Intermittent CalciNeurin Inhibitor Controls—The piCNIc Retrospective Cohort Study Authors: Veronica Bellissimo, Lilia Tran, Gaëlle Bernard‐Tessier, Jean‐Simon Denault, Sarah Pelletier, Andreea‐Adelina Statie, Nathalie Letarte, Geneviève Huard, Julie Morisset, Victor Ferreira Published: 2026 ABSTRACT ABSTRACTBackgroundCalcineurin inhibitors (CNIs) are essential in immunosuppressive therapy after solid organ transplantation (SOT). Their narrow therapeutic index and inter‐ and intra‐individual variability require therapeutic drug monitoring (TDM), but optimal monitoring frequency remains unclear. This retrospective observational cohort study evaluated the impact of a pharmacist‐developed protocol to standardize and reduce CNI monitoring frequency on the number of CNI measurements, the achievement of CNI TDM target, and resource utilization.MethodsData was collected retrospectively from adult liver, kidney, and lung transplant patients hospitalized between February 1 and July 31 of 2023 and 2024 at the Centre Hospitalier de l'Université de Montréal (CHUM). CNI measurements per patient per week, prescription quality and patient safety were compared before and after the protocol's implementation.Results520 hospitalizations were included (254 pre‐ and 266 post‐intervention hospitalizations). Primary analysis showed an adjusted mean reduction of 0.9950 CNI measurements per patient per week (95% CI, 0.6398 to 1.3502; p < 0.0001), corresponding to a 14.0% decrease. Secondary analysis revealed no significant differences in achieving CNI TDM target or dose adjustments between groups. CNI‐related adverse effects were similar in both groups.ConclusionThe development and implementation of a new protocol by pharmacists to standardize and reduce the frequency of CNI monitoring significantly decreased the number of CNI measurements per hospitalized patient, without compromising the achievement of CNI TDM target or patient safety. This approach highlights a valuable strategy for hospitals to manage costs effectively amidst increasing financial pressures without affecting patient outcomes. Abbreviations Centre Hospitalier de l'Université de Montréal Calcineurin inhibitor Solid organ transplantation Therapeutic drug monitoring Introduction Calcineurin inhibitors (CNIs) such as tacrolimus and cyclosporine are the primary immunosuppressive agents prescribed after solid organ transplantation (SOT) [1]. These agents require therapeutic drug monitoring (TDM) due to their narrow therapeutic index and significant inter‐ and intra‐ individual variability [2, 3] CNIs are susceptible to numerous drug interactions, further necessitating close monitoring [4]. TDM also helps minimize adverse effects associated with CNIs, such as nephrotoxicity—one of the most common and feared complications following SOT [5, 6]. Other potential adverse events include neurotoxicity, metabolic disorders, and increased infection risk [1]. Ultimately, TDM is crucial in post‐transplant care to reduce the risk of graft rejection and prevent acute complications [3]. In 2020, The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) published a consensus guideline on the therapeutic monitoring of tacrolimus [7]. The consensus recommendations specified target blood concentration ranges for tacrolimus in SOT and discussed various monitoring strategies and dosing methods [7, 8]. However, the consensus did not provide recommendations regarding the frequency of TDM. Similarly, there are no guidelines addressing the frequency of therapeutic monitoring for cyclosporine. Optimal dosing frequency for these drugs is rarely discussed in current literature. One study, conducted at the Ottawa Hospital focused on the safety and efficacy of reducing tacrolimus dosing to three times per week after the initial seven days of daily dosing in hematopoietic stem cell transplant patients. Prior to this change, all patients were monitored daily. The authors found no statistically significant difference in the proportion of time spent within the therapeutic range between the two groups [9]. Although the study population differs from the SOT population, it highlights current interest in a standardized approach to optimal CNI dosing frequency. Several hospitals in Canada already perform reduced CNI monitoring. This approach appears to be primarily guided by local practices, with no published data available on patient outcomes. CNIs TDM and dose adjustments at the CHUM are managed by the treating transplant physician, with support of clinical pharmacists when consulted. In most patients, daily CNI levels are collected, regardless of organ type or time post‐transplantation. This practice was established prior to the integration of clinical pharmacists to the transplant teams. The reasoning behind this was that many patients admitted to our institution presented with acute illness often affecting CNI pharmacokinetics or requiring rapid drug level adjustments. Daily dosing being available, most physicians adopted this practice. However, there is no evidence that daily monitoring is more effective in achieving therapeutic levels and preventing toxicity while ensuring CNI efficacy. Moreover, according to CNI pharmacokinetics, daily monitoring may lead to premature dose adjustments. The full effect of a CNI dose adjustment is typically observed at steady state [4]. For tacrolimus, with a half‐life of 12 to 31 h [10, 11, 12, 13], this effect takes at least three to seven days, while cyclosporine, with a half‐life of about 18 h [13, 14], shows full effect after a minimum of three days [13, 15]. The lack of a standardized procedure that incorporates the patient's clinical condition to guide CNI therapeutic monitoring frequency is a shortcoming for clinicians. To address this, transplant pharmacists at the CHUM developed a new protocol to standardize and reduce the monitoring frequency of CNIs. This retrospective observational cohort study evaluates the protocol's impact on the frequency of CNI measurements in hospitalized SOT patients and examines its effect on patient care quality and hospital resource utilization. Methods Study Design A retrospective cohort study was carried out to examine the impact of the implementation of a new protocol, developed by clinical pharmacists at the CHUM in November of 2023, which aimed to standardize and to reduce the frequency of in‐patient CNI monitoring (Figure S1). The protocol offered physicians the option for reduced dosing of CNIs in most patients, or daily dosing of CNIs in selected patients. A before‐after design was used, comparing patients hospitalized during the period prior to the protocol implementation (February 1 to July 31, 2023) and those hospitalized during the same period after implementation (February 1 to July 31, 2024). The same calendar period was chosen to minimize external confounding variables. Implementation of New Reduced Frequency CNI Protocol The new protocol was elaborated and introduced to the transplant medical team in November 2023 by members of the clinical transplant pharmacist team. Informational sessions were conducted to explain its application and promote its adoption. The standardized protocol was placed in the patient's chart at the time of admission, to be completed by the prescribing physician. While the use of this new protocol was not mandatory, periodic reminders were sent out by clinical transplant pharmacists to encourage its use. It is important to note that not all transplant clinical pharmacists at our institution were involved in the development of this new protocol. Patients Patients 18 years and older with a liver, kidney and/or lung transplant receiving a CNI were included in the present study. Patients were eligible starting on day 15 after transplantation and stayed for a minimum of 48 h on the transplant ward. The first 14 days after transplant were not subjected to the intervention due to the need for more intensive CNI monitoring during this period, as recommended per clinicians during development of the intervention. Patients were excluded if they were admitted prior to February 1 or if they were discharged after July 31. The reason for hospitalization did not need to be transplant related. All hospitalizations (including repeat hospitalizations) were included in the primary analysis. For the secondary analyses, only the first eligible hospitalization per patient per period was included. The study entry date was the patient's day of admission on the transplant ward for those with a previous transplant and on the 15th day post‐transplant for newly transplanted patients. The exit date was the day of discharge from the transplant ward. All patients were identified from the CHUM archives database and filtered based on hospitalization and admission dates. Outcomes The primary outcome was the difference in mean CNI measurements per patient per week between the two groups. Secondary outcomes assessed the adoption level of the new protocol and its impact on prescription quality, defined as the number of late CNI prescriptions, the proportion of patients needing at least one CNI dose adjustment, and the proportion of patients who had at least one CNI dose modification during hospital stay but was discharged with the same dose as that of admission. Achievement of CNI TDM target was evaluated using standard CHUM CNI therapeutic range targets (Table S1). Potential CNI‐related adverse events were extracted from patient charts, as reported by clinicians during usual care. For descriptive purposes, the characteristics of patients in the post‐intervention group who had daily CNI monitoring were compared with those who received reduced monitoring as per the new protocol. Covariates Demographic information (age, gender), body mass index (BMI), comorbidities, time post‐transplant, type of SOT, as well as pertinent laboratory test results such as creatinine, hematocrit and albumin at the time of admission were collected. Concomitant immunosuppressive drugs and reason of admission were also identified. All covariates were considered clinically relevant as they could affect the monitoring of CNIs. Statistical Analysis All data was analyzed with the help of a statistician using SAS version 9.4. Continuous quantitative variables are described with means and standard deviation. Categorical variables are described with proportions (%). Analysis for the primary objective was performed using a mixed model for repeated measures (MMRM) with an alpha of 0.05, accounting for dependencies between groups since all readmissions were included. The mean difference in the amount of CNI measurements per patient per week was calculated with a 95% confidence interval. Intention‐to‐treat analysis was used in both primary and secondary outcomes. A per‐protocol analysis was also performed to account for protocol deviations, which was defined as [1] CNI measurements collected more frequently than three times per week in the post‐intervention group without justification, or [4] patients for whom the physician or pharmacist did not fill the standardized prescription form. Subgroup analyses evaluated outcomes based on the type of transplanted organ, the type of CNI (tacrolimus or cyclosporine), and newly transplanted patients hospitalized post‐transplant versus previously transplanted patients hospitalized for other reasons. A sensitivity analysis explored the impact of hospitalization duration on outcomes. All analyses adjusted for the confounding factors of gender, age, organ type, and time post‐transplant. Missing data were considered “missing at random,” therefore no analysis was conducted for these occurrences. Ethics Approval The protocol was submitted to and approved by the ethics research committee of the CHUM. All data was collected retrospectively from medical electronic records at the CHUM into a standardized data collection form designed in REDCap. A separate Excel sheet containing patient personal information was also kept on the CHUM server with password protected access to ensure confidentiality. Access to all the data was restricted to the authors who participated in this study. Results Patients Of the 676 hospitalizations assessed for eligibility, 156 were excluded. In total, 520 hospitalizations were included in the study, of which 254 hospitalizations belonged to the pre‐intervention group and 266 to the post‐intervention group (Figure 1). Study flow diagram. CHUM = Centre hospitalier de l'Université de Montréal, CNI = calcineurin inhibitor. Both groups had similar baseline characteristics. Potential confounding factors, such as the type of organ transplanted, age, new versus previous transplant and relevant laboratory findings were similar between both groups (Table 1). Mean overall hospital length of stay (LOS) was significantly different between groups. However, mean LOS on the transplant ward was not different between the groups (Table 2). TABLE 1Baseline characteristics of study population a .CharacteristicsPre‐intervention group (N = 215)Post‐intervention group (N = 219) p‐valueAge (years) – mean ± SD58 ± 1259 ± 130.505Gender (female) – no. (%)98 (45.6)99 (45.2)0.937BMI (kg/m2) – mean ± SD25 ± 526 ± 60.235 Type of transplant b – no. (%)Kidney93 (43.3)92 (42.0)0.793Lung72 (33.5)83 (37.9)0.338Liver56 (26.0)51 (23.3)0.505Pancreas7 (3.3)7 (3.2)0.972Multi‐organ13 (6.0)14 (6.4)0.881 Transplant Specialty responsible for CNI prescription – no. (%)0.683Nephrology92 (42.8)87 (39.7)Pneumology72 (33.5)82 (37.4)Hepatology51 (23.7)50 (22.8)Transplant redo – no. (%)23 (10.7)19 (8.7)0.476Newly transplanted patients – no. (%)44 (21.1)57 (26.0)0.226Time post‐transplant (days) – mean ± SD2213 ±2 6942227 ± 27950.957 Comorbidities – no. (%)Diabetes99 (46.0)104 (47.5)0.763Hypertension138 (64.2)130 (59.4)0.301Inflammatory bowel disease8 (3.7)9 (4.1)0.835Cystic fibrosis4 (1.9)8 (3.7)0.255CKD98 (45.696 (43.8)0.715Chronic hemodialysis12 (5.6)11 (5.0)0.795 Type of CNI – no. (%)Tacrolimus200 (93.0)203 (92.7)0.772Cyclosporine17 (7.9)19 (8.7)0.894 CNI discontinuation before discharge – no. (%) 1 (0.5)4 (1.8)0.372 CNI administration route c – no. (%)PO214 (99.5)217 (99.1)1.000Nasogastric tube23 (10.7)24 (11.0)0.930 Concomitant immunosuppressants – no. (%)Azathioprine16 (7.4)9 (4.1)0.136Corticosteroids157 (73.0)165 (75.3)0.581Sirolimus0 (0.0)1 (0.5)1.000MMF/ MPA106 (49.3)112 (51.1)0.702Baseline creatinine (umol/L) – mean ± SD124 ± 95132 ± 1100.406Hematocrit at admission – mean±SD0.33 ± 0.070.52 ± 2.880.323Albumin at admission (g/L) – mean ± SD33 ± 933 ± 60.676Abbreviation: BMI = body mass index, CKD = chronic kidney disease, CNI = calcineurin inhibitor, MMF = mycophenolate mofetil, MPA = mycophenolic acid, PO = per os. a This table includes the first hospitalization of each patient in the pre‐ and post‐intervention groups. Rehospitalizations are not included. b Multi‐organ transplant patients are also included in the individual type of organ transplant. c During hospitalization, patients could have both CNI routes of administration.John Wiley & Sons, Ltd. Baseline characteristics of study population a . CNI discontinuation before discharge – no. (%) Abbreviation: BMI = body mass index, CKD = chronic kidney disease, CNI = calcineurin inhibitor, MMF = mycophenolate mofetil, MPA = mycophenolic acid, PO = per os. This table includes the first hospitalization of each patient in the pre‐ and post‐intervention groups. Rehospitalizations are not included. Multi‐organ transplant patients are also included in the individual type of organ transplant. During hospitalization, patients could have both CNI routes of administration. TABLE 2Characteristics of hospitalizations a .Pre‐intervention group (N = 254)Post‐intervention group (N = 266) p‐value Reason for hospitalization – no. (%)Pyelonephritis13 (5.1)17 (6.4)Pneumonia14 (5.5)18 (6.8)Gastroenteritis6 (2.4)1 (0.4)New transplant29 (11.4)27 (10.2)Cholecystitis1 (0.4)0 (0.0) Transplant rejection (acute or chronic) 5 (2.0)4 (1.5)AKI4 (1.6)5 (1.9)Other81 (31.9)86 (32.3)Mean total LOS (days) – mean ± SD16 ± 1620 ± 230.024Mean total transplant ward LOS (days) – mean ± SD11 ± 1212 ± 140.268 Number of hospitalizations per patient b – no. (%)1 hospitalization183 (72.0)183 (68.8)2 hospitalizations56 (22.0)54 (20.3)3 hospitalizations6 (2.421 (7.9)4 hospitalizations4 (1.6)8 (3.0)5 hospitalizations c 5 (2.0)0 (0.0)Abbreviation: AKI, acute kidney injury, LOS, length of stay. a This table includes all hospitalizations in the pre‐ and post‐intervention groups. b 35 patients were hospitalized in both the pre‐ and post‐intervention groups. c The maximum number of hospitalizations in a given period (pre‐ or post‐intervention) is 5.John Wiley & Sons, Ltd. Characteristics of hospitalizations a . Transplant rejection (acute or chronic) Abbreviation: AKI, acute kidney injury, LOS, length of stay. This table includes all hospitalizations in the pre‐ and post‐intervention groups. 35 patients were hospitalized in both the pre‐ and post‐intervention groups. The maximum number of hospitalizations in a given period (pre‐ or post‐intervention) is 5. Patients were primarily male adults with an average age of 58. Kidney transplants were the most common, followed by lung and liver transplants, with 6% being multi‐organ transplants. Most patients were hospitalized for reasons other than a transplant procedure. Most patients were receiving tacrolimus (93%), and concomitant immunosuppressive therapy was similar across both groups, with corticosteroids and mycophenolate acid being the most frequent concomitant agents prescribed (Table 1). Primary Outcome Intention‐to‐Treat A total of 520 patients were included in the intention‐to‐treat analysis. The unadjusted difference in the frequency of CNI measurements per patient per week of hospitalization was 1.0192 (95% confidence interval [CI], 0.6195 to 1,4189; p < 0,0001), representing a 14.59 % decrease in the frequency of CNI monitoring in the post intervention group (Figure 2). Results for the primary outcome of mean CNI measurements per patient per week. All analyses are adjusted for gender, age, type of transplant and time post‐transplant. CNI = calcineurin inhibitor. Adjusting for age, sex, organ transplant type and time post‐transplant, the difference in the frequency of CNI measurements performed per patient per week of hospitalization was 0.9950 (95% CI, 0.6398 to 1.3502; p < 0.0001). This represents a 14.02 % decrease in the frequency of CNI monitoring in the post intervention group. Per‐Protocol A per‐protocol analysis was conducted which included all patients who did not deviate from the protocol, as defined previously. A total of 369 patients were included (254 and 115 patients in the pre and post‐intervention group respectively). The difference in means of CNI measurements per patient per week between the pre‐ and post‐intervention group was 1.4476 (95% CI, 0.9686 to 1.9266; p < 0.0001). This represents a 20.72% decrease in the number of CNI measurements in the post‐intervention group. The adjusted mean difference in CNI measurements per patient per week was 1.2875 (95% CI, 0.8551 to 1.7199; p < 0.0001), which represents a 18.21% reduction. The per‐protocol analysis showed a larger effect size when compared to the intention‐to‐treat population, indicating that when the protocol was respected, a larger decrease in the number of CNI measurements per patient per week was observed. Secondary Outcomes The adoption rate of the new protocol was 43.72% (95% CI, 36.41% to 51.23%) in the post‐intervention group. No significant differences in the achievement of CNI TDM target or the number of dose adjustments between groups was observed. Specifically, the proportion of patients discharged on the same dose of CNI despite requiring adjustments during hospitalization was similar between groups (37.8% vs. 34.48%; p = 0.6874). Additionally, there were no significant differences in the proportion of supra‐ or sub‐therapeutic CNI dosages. Safety Acute graft rejection episodes were slightly more frequent in the post‐intervention group (3.32% vs. 6.11%). All episodes were present upon admission and no acute rejection episode developed during hospital stay. CNI‐related adverse events were more frequently reported in the pre‐intervention group, compared to the post intervention group (25 and 16 patients, respectively). Acute kidney injury (AKI) was the most common, affecting 18 patients (72%) pre‐intervention and 10 patients (62.5%) post‐intervention. Tremors were reported by 7 patients (28%) pre‐intervention and 2 patients (12.5%) post‐intervention. Overall, although protocol adoption rates were below 50%, the secondary findings seem to indicate that applying reduced CNI monitoring to specific patients does not compromise capacity to achieve CNI TDM target or patient safety. Additional Analyses The proportion of patients with a CNI monitoring frequency of less than 0.57 measurements per day (i.e., less than 4 times per week) increased in the post‐intervention group in both the intention‐to‐treat and per‐protocol analyses, compared to the pre‐intervention group (pre‐intervention: n = 23 [9%]; post‐intervention ITT: n = 61 [23%], post‐intervention PP: n = 31 [27%]). Primary outcomes were statistically significant in renal and liver transplant patients, with decreases of 1.5260 (95% CI, 0.9016 to 2.1503; p < 0.0001) and 1.2781 in CNI measurements per patient per week (95% CI, 0.5046 to 2.0516; p = 0.0026), respectively. For lung transplant patients however, the reduction was not statistically significant, with a decrease of 0.2552 (95% CI, ‐0.1997 to 0.7101; p = 0.2539). Analysis based on transplant timing (new versus previous) indicated that the reduction in CNI monitoring was consistent across both groups. For patients with previous transplants, the frequency decreased by 0.9553 levels per week (95% CI, 0.5428 to 1.3677; p < 0.0001), while new transplant recipients experienced a reduction of 1.0830 measurements per week (95% CI, 0.4243 to 1.7416; p = 0.0015). Analysis by CNI type revealed a more pronounced significant reduction in CNI monitoring for cyclosporine. Patients on cyclosporine saw a decrease of 2.6671 CNI measurements per week (95% CI, 1.4438 to 3.8904; p = 0.0006). This is likely due to current practices favoring tacrolimus as the first‐line immunosuppressant for new transplants, with cyclosporine remaining mostly in older, more stable patients. Meanwhile, patients on tacrolimus had a significant reduction of 0.7995 CNI measurements per week (95% CI, 0.4314 to 1.1675; p < 0.0001). A sensitivity analysis categorizing hospital stays by duration (< 7 days, 7‐14 days, and > 14 days) did not reveal statistically significant differences on the primary outcomes. Descriptive analyses assessed characteristics of patients with daily CNI monitoring compared to those monitored three times weekly or less. These results were similar to those observed through the subgroup analyses mentioned above (Table S2). Discussion This study shows a statistically significant reduction in CNI measurements following the implementation of a new protocol standardizing and reducing the frequency of CNI monitoring, without adversely affecting the achievement of CNI TDM target, dose adjustments or patient safety. Both the intention‐to‐treat and per‐protocol analyses showed a significant decrease in CNI measurements after implementing the new protocol. The per‐protocol analysis showed a larger effect size, which was expected since most protocol deviations resulted from physicians continuing to apply practices consistent with those used in the pre‐intervention group. Renal and liver transplant patients contributed the most to the observed primary outcome, in contrast to lung transplant patients, who did not demonstrate a significant reduction in frequency of CNI measurements. This may be attributed to higher overall complication risks associated with lung transplants, leading to more cautious and less frequent prescription of reduced CNI monitoring. Additionally, other factors, such as the availability of prescribers to discuss and adopt the protocol, likely influenced the results observed. The proportion of patients discharged on the same dose of CNI despite requiring adjustments during hospitalization was similar between groups, suggesting potential futility of increased CNI monitoring in improving immunosuppressive control of select patients. Acute rejection episodes, as reported by physicians in patient charts, were more frequent in the post‐intervention group. However, all episodes were present upon admission and no episode developed during hospital stay. Since the studied intervention was applied at the time of admission and was not examined in the outpatient setting, it could not be considered the cause for this increase. As was allowed per the intervention, all patients admitted with acute rejection in the post intervention group were monitored with daily CNI measurements. Regarding CNI levels, 3 patients in the pre‐intervention and 2 patients in the post‐intervention group were found to have had at least one subtherapeutic CNI level. All patients were also treated with a second or third immunosuppressant, mostly mycophenolate and/or prednisone. Limitations Internal Validity While results from all primary analyses are statistically significant, the impact of the intervention on CNI measurements may be underestimated. Some patients were initially prescribed daily dosing before being targeted by the reduced CNI monitoring intervention (e.g., daily monitoring for 7 days, then three times per week afterwards, see “Specific clinical situation” section in Figure S1. However, reduced CNI measurements after the initial daily dosing period was not implemented as prescribed. Thus, while the protocol was appropriately utilized by the medical team, its application was not adequately followed, likely due to administrative shortcomings. The observed effect size could have potentially been larger if the reduced schedule had been consistently applied. While CNI‐related adverse effects were reported in the study, their evaluation was likely underestimated, as it relied on medical notes, which do not always document such effects, making it challenging to determine whether a patient experienced them. Confounding bias in this study was minimal, as the two patient groups were selected from the same time period in consecutive years, with no practice change occurring aside from the introduction of the studied intervention. Furthermore, all adjusted analyses remained statistically significant. A standardized data collection form minimized information bias among investigators, although extra assistance from pharmacy students introduced an additional risk of information bias. To limit this, 10% of each student's data was verified by a pharmacy resident. The low protocol adoption rate of 43.72% in the post‐intervention group can be attributed to several factors. One potential reason is protocol misplacement in the patient file which led to its misclassification in electronic medical records. This potentially underestimated adherence to protocol. Additionally, despite a transition period to help the medical team adapt to the new practice, the new protocol was not systematically flagged in patient files, potentially leading to its omission when prescribing CNI monitoring frequency. This was particularly evident in newly transplanted patients in the post‐intervention group, where protocol implementation was suboptimal at day 15 after transplant. In addition, protocol adoption in the lung transplant population was lower than anticipated. The overall clinical fragility of this population, in addition to the high pill burden, significant drug interaction potential, and rapidly evolving clinical conditions, may have contributed to practitioners’ hesitancy in substantially altering their practice, contributing to the low adoption rate observed. However, despite this low rate of adoption, a significant reduction in CNI monitoring frequency was observed. This could support the idea that the simple process of collaborating on the development of the protocol may have had an indirect impact on prescribing practices by raising awareness in physicians. In the per‐protocol analysis, the proportion of patients prescribed CNI measurements less than four times a week tripled in the post‐intervention group. These patients were mostly kidney and liver transplants recipients, further suggesting lower protocol adoption among lung transplant patients. Surprisingly, a substantial number of patients in the post‐intervention group continued to receive more than four CNI measurements per week, even in per‐protocol analysis. This may be partially explained by some clinicians’ reluctance to modify their practice patterns and reduce CNI monitoring when clinically appropriate. Additionally, because CNI troughs are drawn during the night shift by less experienced staff, some measurements may have been performed routinely even when not indicated. Finally, given that the protocol allowed for daily monitoring in specific clinical situations, these findings may also reflect the high degree of complications observed in our patients upon admission to our institution. To assess achievement of CNI TDM targets, the CHUM's standard CNI monitoring targets per organ were applied for all patients. For multi‐organ transplant patients, the targets applied were based on the transplanted organ requiring the most intensive immunosuppression. We acknowledge physician‐defined targets might have varied slightly in some patients, although this is expected to be a minority of patients. Considering the large number of patients and long time periods in each group, these exceptions are expected to be unlikely significant and equally distributed in each group. Considering these limitations, no differences in achieving CNI TDM targets between the groups were observed and out‐of‐target measurements were infrequent. Moreover, since there were few multi‐organ transplant patients and they were equally distributed between groups, it is unlikely that this method of assessment significantly impacted the overall results. External Validity The protocol offers a standardized approach to implementing a reduced CNI monitoring frequency. This can be applied to both newly transplanted patients (after 14 days) and long‐term transplant recipients, regardless of whether they are on oral cyclosporine or tacrolimus. In general, this reduced monitoring frequency can be applied to patients with renal and liver transplants who are not admitted to the emergency department or intensive care. Only the first hospitalization in each period was analyzed to describe patient characteristics (Table 1). As a result, the population demographic may overlook comorbidities developed during subsequent rehospitalizations. Although reduced CNI monitoring is generally less likely to be applied to sicker patients, due to their increased vulnerability to CNI blood level variability, the protocol also permitted for reduced monitoring for these individuals. This aspect of the protocol allowed for individualization according to patient needs and physician opinion, which better reflects usual practice. Overall, the protocol enables clinicians to effectively tailor CNI TDM frequency to meet their patients' specific requirements. Economic and environmental benefits can also be inferred. In our institution, the cost of each tacrolimus level is 12.90 Canadian dollars (CAD$), while cyclosporine levels are 13.52 CAD$ [16]. Over the course of 4 months, the new protocol led to a total economic saving of around 5600 CAD$ in test tube and CNI level analysis cost, and saved 2.6 kg in plastic test tubes. These savings do not account for additional benefits in labor costs or significant efficiency improvements for the entire transplant team (including pharmacy services), which are expected from the reduced frequency of CNI prescriptions following each blood level. Future Directions Since adherence to the protocol reduces dosing frequency without affecting negatively patient care, strategies to enhance protocol adoption should be implemented in practice, such as systematically incorporating the new protocol into admission prescriptions in each patient's file. An interesting solution for long‐term practice change could also be to increase education and awareness initiatives aimed at physicians. Furthermore, the frequency of CNI monitoring should be regularly reassessed during hospitalization to reflect changes in the patient's condition, such as stabilization following an acute phase. Future studies could assess the impact of including clinical pharmacists in the decision process of prescribing CNI TDM in hospitalized patients to optimize resource use. Conclusion In this retrospective cohort study, the implementation of a new protocol developed by clinical pharmacists to standardize and reduce the frequency of CNI monitoring significantly decreased the number of CNI measurements per patient without compromising CNI TDM target achievement or patient safety. The findings suggest that less frequent monitoring may help optimize resource use while maintaining desired clinical outcomes. This study highlights the potential of a standardized protocol for CNI adjustments to enhance healthcare efficiency by encouraging tailored CNI TDM for SOT patients. Author Contributions Veronica Bellissimo, Gaëlle Bernard‐Tessier, and Lilia Tran contributed equally to the study design, data collection, data analysis/interpretation, and drafting of the article. Jean‐Simon Denault, Sarah Pelletier, Andreea‐Adelina Statie, Nathalie Letarte, and Victor Ferreira contributed to the study design and the critical revision of the article. Geneviève Huard and Julie Morisset contributed to the revision of the article. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting Information